Searchable abstracts of presentations at key conferences in endocrinology

ea0022s1.6 | European networks | ECE2010

The European Registry on Cushing's syndrome (ERCUSYN) database: first year experience

Webb Susan , Santos Alicia , Trainer Peter , Strasburger Christian , Lamberts Steven , Wass John , Feelders Richard , Franz Holger

The ERCUSYN (European Registry on Cushing’s syndrome (CS)) study is a project funded by the European Commission Public Health Program (PHP 800200), of which the ESE is one of the 41 Partners from 25 countries. The aims include obtaining prospective and follow-up data at EU level on epidemiology, mortality, outcome of therapies, co-morbidities, assessment of diagnostic and therapeutic strategies, quality of life evaluation using a disease-generated questionnaire (CushingQo...

ea0022p41 | Adrenal | ECE2010

Response of human adrenocortical carcinoma to mitotane treatment in vitro

van Koetssveld Peter , van Rutte Karlijn , Waaijers Marlijn , de Krijger Ronald , Lamberts Steven , Feelders Richard , de Herder Wouter , Hofland Leo

Introduction: Adrenocortical carcinoma (ACC) is a rare, but highly malignant endocrine tumor. Surgery is the primary choice of treatment. In case of inoperable disease or tumor recurrence, therapy with the adrenolytic drug mitotane is usually applied. Plasma mitotane concentrations of >14 mg/l (50 μM) seem required for an effect on tumor mass. Despite its clinical use, the effects of mitotane on cell proliferation and hormone production have been poorly investigated <...

ea0037ep94 | Adrenal cortex | ECE2015

Combined effects of sirolimus and mitotane in the inhibition of growth in human adrenocortical carcinoma cells

De Martino Maria Cristina , van Koetsveld Peter M , Feeldes Richard A , Lamberts Steven W J , de Herder Wouter W , Colao Annamaria , Pivonello Rosario , Hofland Leo J

Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and scant treatment options. Mitotane alone, or in combination with cytotoxic chemotherapy, represents the referral current treatment for patients with unresectable ACC. Recent studies have shown that mTOR inhibitors suppress growth of ACC cells. This study aimed at evaluating the effects of mitotane in combination with mTOR inhibitors. In H295 and SW13 cells we tested the effects of a 6 day treatment with increa...

ea0029p10 | Adrenal cortex | ICEECE2012

The mTOR-pathway in normal and tumoral human adrenocortical tissues

De Martino M. , van Koetsveld P. , Feelders R. , Sprij-Mooij D. , Waaijers M. , Lamberts S. , de Herder W. , Colao A. , de Krijger R. , Pivonello R. , Hofland L.

Background: Novel treatment options are required for patients with adrenocortical carcinomas (ACCs). mTOR-inhibitors are anti-neoplastic drugs that target the mTOR-pathway.Aim: To describe the expression of the mTOR-pathway in normal and pathological adrenocortical tissues.Methods: We evaluated mRNA expression levels of mTOR, S6K and 4EBP1 in 10 normal adrenals (NA), 11 adrenal hyperplasias (AH), 19 adrenal adenomas (ACA) and 26 AC...

ea0029p11 | Adrenal cortex | ICEECE2012

Measurement of cortisol in scalp hair can be a new tool in the diagnosis and follow-up of patients with Addison’s Disease and (cyclic) Cushing’s Syndrome

Manenschijn L. , Koper J. , van den Akker E. , de Heide L. , de Jong F. , Feelders R. , Lamberts S. , van Rossum E.

Introduction: The diagnosis of Cushing’s Syndrome (CS) and in particular cyclic CS can be complicated. Standard screening tests for CS are the measurement of cortisol in 24-hours urine collections and in midnight saliva. In case of cyclic CS, results of these tests can be normal in between periods of hypercortisolism. The development of a method to measure cortisol in scalp hair provides the opportunity to investigate historical cortisol levels of months to years ago, wit...

ea0029p1073 | Neuroendocrinology | ICEECE2012

Normalization of cortisol levels in Cushing's disease after medical pretreatment before surgery: effects on somatostatin receptor subtype expression and in vitro response to somatostatin analogs.

Pas R. van der , Feelders R. , Bruin C. de , Pereira A. , Sprij-Mooij D. , Waaijers M. , Schulz S. , Lamberts S. , Hofland L.

Introduction: Corticotroph pituitary adenomas that cause Cushing’s disease (CD) predominantly express the dopamine 2 receptor (D2) and somatostatin receptor subtype (sst) 5. The expression of sst2 is relatively low because of downregulating effects of high endogenous cortisol levels. This may explain why the sst2-preferring somatostatin analog octreotide is not effective in CD. To assess whether normalization of urinary free cortisol (UFC) excretion modulates the sst expr...

ea0026p84 | Endocrine tumours and neoplasia | ECE2011

The demethylating agent 5-aza-2-deoxycytidine upregulates somatostatin type 2 receptor expression and enhances internalization of radiolabeled somatostatin analogue in human carcinoid tumour cells

Veenstra M J , van Koetsveld P M , Farrel W E , Dogan F , Waaijers A M , Sprij-Mooij D M , Lamberts S W J , Vitale G , Hofland L

Introduction: Neuroendocrine tumors (NET) are rare tumors originating from various types of neuroendocrine cells. The somatostatin receptor type 2 (sst2) is expressed in NET cells and is a target for therapy with somatostatin analogues.Epigenetic changes including methylation of DNA at CpG dinucleotides, and particularly in the promoter region of genes can inhibit transcription. Methylation can be inhibited by cytidine analogues such as 5-aza-...

ea0026p188 | Neuroendocrinology | ECE2011

Glucocorticoid receptor gene polymorphisms are associated with disease course during pregnancy and the post-partum period in rheumatoid arthritis

Quax R A M , de Man Y A , Koper J W , Willemsen S P , Lamberts S W J , Hazes J M W , Dolhain R J E M , Feelders R A

Background: The mechanism underlying the spontaneous improvement of rheumatoid arthritis (RA) during pregnancy and the subsequent post-partum flare is incompletely understood. The glucocorticoid receptor (GR) polymorphisms Bcl1 and 9β are associated with an increased and decreased glucocorticoid sensitivity respectively. We examined the relation between carriership of these functional GR polymorphisms and disease course during pregnancy and post-partum in RA...

ea0026p351 | Steroid metabolism | ECE2011

Evaluation of a method to measure long term cortisol levels in health and disease

Manenschijn L , Koper J W , van den Akker E L T , Feelders R A , Lamberts S W J , van Rossum E F C

Introduction: Elevated levels of cortisol are known to induce a wide range of pathology, e.g. abdominal obesity, type 2 diabetes and cardiovascular disease. Measuring serum and saliva cortisol is limited to one time point. Measurement of cortisol in scalp hair is a recently developed method to measure long term cortisol levels and might reflect cortisol exposure in patients with hyper- or hypo-cortisolism and in healthy persons. Our aims were to explore this measurement of cor...

ea0020p52 | Adrenal | ECE2009

Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines

De Martino Maria Cristina , van Koetsveld Peter , Sprij-Mooij Diana , Feelders Richard A , Lamberts Steven W J , de Herder Wouter W , Colao Annamaria , Pivonello Rosario , Hofland Leo J

Background: Adrenocortical carcinoma (ACC) is an uncommon malignancy with a still scantily understood pathogenesis and generally poor prognosis. Surgery, performed at early stages, offers the best chance for cure, but unfortunately, it is often noncurative. Medical treatment produced disappointing responses. mTOR inhibitors, such as sirolimus (S) and temsirolimus (T), are promising antineoplastic drugs in several types of carcinomas.Methods: To evaluate ...